Clinical Trial Update: Tocilizumab for the Prevention of Graft Versus Host Disease After Cord Blood Transplantation [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating tocilizumab to prevent graft-versus-host disease after cord blood transplantation has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia
• Hodgkin Lymphoma
• Myelodysplastic Myeloproliferative Neoplasms
• Myelodysplastic Syndromes
• Myeloproliferative Neoplasms
• Non-hodgkin Lymphoma

Drugs mentioned

• Tocilizumab (tocilizumab)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia | Phase 2 | Status: COMPLETED